Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 939-946

  Giralt, S A ^a   Mangan, K F ^b   Maziarz, R T ^c   Bubalo, J S ^c   Beveridge, R ^d   Hurd, D D ^e   Mendoza, F L ^a   Rubenstein, E B ^f   DeGroot, T J ^f   Schuster, M W ^g  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Fox Chase Temple BMT Program   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Fairfax Northern Virginia Hematology Oncology   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f EISAI INC   (United States)

^g STONY BROOK UNIVERSITY   (United States)

Author keywords

High dose melphalan; Myeloma; Nausea; Palonosetron

Indexed keywords

DEXAMETHASONE; MELPHALAN; PALONOSETRON; PLACEBO;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FLATULENCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 79953331734     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq457     Document Type: Article

References (35)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008, 111: 2962-2972.
2. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol 2008, 26: 2895-2900.
3. Gasparetto C. Stem cell transplantation for multiple myeloma. Cancer Control 2004, 11: 119-129.
4. Viner CV, Selby PJ, Zulian GB et al. Ondansetron-a new safe and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemother Pharmacol 1990, 25: 449-453.
5. Ballen KK, Hesketh AM, Heyes C et al. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 2001, 28: 1061-1066.
6. Abbott B, Ippoliti C, Hecth D et al. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 2000, 25: 1279-1283.
7. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. J Clin Oncol 2006, 24: 2932-2947.
8. Einhorn LH, Rapoport B, Koeller J et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005, 13: 112-116.
9. Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Cancer Network 2007, 5: 51-59.
10. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapyinduced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006, 17: 20-28.
11. Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2006, 2: 591-602.
12. Rojas C, Stathis M, Thomas AG et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008, 107: 469-478.
13. Rojas C, Thomas A, Zhang J et al. Palonosetron, but not ondansetron or granisetron, exhibits receptor internalization and long-term inhibition of function. J Oncol Pharm Pract 2008, 14: 100 (Abstr TS4).
14. Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the Functional Living Index-Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006, 4: 35-41.
15. Gralla R, Lichinitser M, Van der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003, 14: 1570-1577.
16. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003, 98: 2473-2482.
17. Aapro M, Grunberg S, Manikhas G et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006, 17: 1441-1449.
18. Einhorn LH, Brames MJ, Dreicer R et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007, 15: 1293-1300.
19. Massa E, Astara G, Madeddu C et al. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol 2009, 70: 83-91.
20. Lorusso V, Spedicato A, Petrucelli L et al. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer 2009, 17: 1469-1473.
21. Adel NG, Khan A, Lucarelli C. Use of palonosetron 0.25 mg IV daily and incidence of nausea and vomiting in patients undergoing bone marrow transplantation (BMT). J Clin Oncol 2006, 24 (18 Suppl): 664S (Abstr 16510).
22. Lopez-Jimenez J, Martin-Ballesteros E, Sureda A et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006, 91: 84-91.
23. Trifilio S, Kaniecki K, Zook J et al. Long-acting serotonin antagonist palonosetron to prevent nausea and vomiting after high-dose melphalan and autograft in myeloma. Blood 2006, 108: 401b (Abstr 5239).
24. Osoba D, Zee B, Warr D et al. Quality of life studies in chemotherapy-induced emesis. Oncology 1996, 53 (Suppl 1): 92-95.
25. Bewick V, Cheek L, Ball J. Statistics review 10: further nonparametric methods. Crit Care 2004, 8: 196-199.
26. Campagnaro E, Saliba R, Giralt S et al. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer 2008, 112: 1617-1624.
27. Trigg ME, Inverso DM. Nausea and vomiting with high dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplant 2008, 42: 501-508.
28. Fox-Geiman MP, Fisher SG, Kiley K et al. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant 2001, 7: 596-603.
29. Hickok JT, Roscoe JA, Morrow GR et al. Effect of nausea vs. vomiting on patients' quality of life during chemotherapy. J Clin Oncol 2006, 24: 471s (Abstr 8514).
30. Martin CG, Rubenstein EB, Elting LS et al. Measuring chemotherapy-induced nausea and emesis. Cancer 2003, 98: 645-655.
31. Slaby J, Trneny M, Prochazka B, Klener P. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 2000, 47: 319-322.
32. Bubalo JS, Leis JF, Curtin PT et al. A randomized double blinded pilot trial of aprepitant vs placebo combined with standard antiemetics during conditioning therapy for hematopoietic stem cell transplantation (HSCT). J Clin Oncol 2007, 25: 9112.7.
33. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000, 18: 3409-3422.
34. Paul B, Trovato JA, Thompson J et al. Efficacy of aprepitant in patients receiving high dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010, 16: 45-51.
35. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21 (Suppl 5): v232-v243.